Preferences for chemotherapy in patients with advanced non-small cell lung cancer: Descriptive study based on scripted interviews

British Medical Journal

Volumn 317, Issue 7161, 1998, Pages 771-775

  Silvestri, Gerard ^a   Pritchard, Robert ^b   Welch, H Gilbert ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; DISEASE SEVERITY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SYMPTOM;

EID: 0032547529     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.317.7161.771     Document Type: Article

References (16)

1. Parker S, Tong T, Bolden S, Wingo P. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Ginsberg R, Kris M, Armstrong J. Cancer of the lung: non-small cell lung cancer. In: DeVita JV, Hellman S, Rosenberg S, eds. Cancer: principles and practice of oncology. Philadelphia: JB Lippincott, 1993:673-723.
3. Grilli R, Oxman A, Julian J. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 1993;11:1866-72.
4. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs supportive care in advanced non-small cell lung cancer: results of a meta-analysis of the literature. Chest 1994;106:861-5.
5. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993;342:19-21.
6. Richards MA, Ramirez AJ, Degner LF, Fallowfield LJ, Maher EJ, Neuberger J. Offering choice of treatment to patients with cancer: a review based on symposium held at the 10th annual conference of the British Psychosocial Oncology Group, December 1993. Eur J Cancer 1995;31A:112-6.
7. Yellen S, Cella D, Leslie W. Age and clinical decision-making in oncology patients. J Natl Cancer Inst 1994;86:1766-70.
8. McQuellon RP, Muss HB, Hoffman SL, Russell G, Craven B, Yellen SB. Patient preferences for treatment of metastatic breast cancer: a study of women with early breast cancer. J Clin Oncol 1995;13:858-68.
9. Sox H, Blatt M, Higgins M, Marton K. Medical decision making, Boston: Butterworths, 1988.
10. Read J, Quinn R, Berwick D, Finebergh HF, Weinstein M. Preferences for health outcomes. Comparison of assessment methods. Med Decis Making 1984;4:315-29.
11. Nord E. Methods for quality adjustment of life years. Med Decis Making 1992;34:559-69.
12. Stiggelbout AM, Kiebert GM, Kievit J, Leer JW, Stoter G, de Haes JC. Utility assessment in cancer patients: adjustment of time tradeoff scores for the ulility of life years and comparison with standard gamble scores. Med Decis Making 1994;14:82-90.
13. Kassirer J. Incorporating patients' preferences into medical decisions. N Engl J Med 1994;330:1895-6.
14. McNeil B, Pauker S, Sox H, Tversky A. On the elicitation of preferences for alternative therapies. N Engl J Med 1982;306:1259-62.
15. Slevin ML, Stubbs L, Plant HJ, Wilson P, Gregory W, Armes PJ, et al. Attitudes to chemotherapy; comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990;300:1458-60.
16. Brundage MD, Davidson JR, Mackillop WJ. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol 1997;15:330-40.